NCT06612762
Naringenin Supplementation in Bone Fracture Patients
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved at least 2 months later.
See at-risk trials from Shahid Beheshti University of Medical Sciences
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 9 words
- Primary completion pushed from Oct 19, 2026 to Jan 16, 2027
- Study completion pushed from Nov 2, 2026 to Mar 15, 2027
- Study description revised
- Minor Primary completion pushed from May 19, 2026 to Oct 19, 2026
- Study completion pushed from Jun 1, 2026 to Nov 2, 2026
- Minor Primary completion date: Feb 19, 2026 to May 19, 2026
- Study completion date: Mar 12, 2026 to Jun 1, 2026
- Notable Primary completion date: Jul 31, 2025 to Feb 19, 2026
- Study completion date: Aug 31, 2025 to Mar 12, 2026
- Minor Primary completion date: Mar 31, 2025 to Jul 31, 2025
- Study completion date: May 31, 2025 to Aug 31, 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Oct 1, 2024 to Nov 3, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Circulating inflammatory markers
Timeframe: Baseline, 14 days post-surgery, and 90 days post-surgery.
Secondary (2)
The rate of bone fusion
Oswestry disability index
Arms and interventions
NaringeninExperimental
The daily ingestion of capsules containing naringenin
ControlPlacebo comparator
Patients will receive placebo capsules
Dietary supplements: The daily ingestion of capsules containing naringenin, Placebo
Sites
1 site in 1 country
- Ayatollah Taleghani Educational HospitalTehran, Iran